Evidence from experimental and human studies has shown that SCD1 participates in the modulation of metabolic syndrome (MS)-associated phenotypes [1], including obesity [2], insulin resistance (IR) [3,4], and nonalcoholic fatty liver disease (NAFLD) [5,6], and it has been suggested that Scd1 is required for the onset of diet-induced hepatic IR in rodents [4]. Here, SCD is linked to myeloid sarcoma.